ReviewWorld journal of microbiology & biotechnology2017
Nature's combinatorial biosynthesis and recently engineered production of nucleoside antibiotics in Streptomyces.
Review in World journal of microbiology & biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks.Natural products and bioprospecting · 2025Review
- Rapid access to the core of malayamycin A by intramolecular dipolar cycloaddition.Beilstein journal of organic chemistry · 2025Article
- Chromosome architecture as a determinant for biosynthetic diversity inMicrobial genomics · 2024Article
- Biochemical Characterization of an Arabinoside Monophosphate Specific 5'-Nucleotidase-like Enzyme fromBiomolecules · 2024Article
- Review
- Actinomycetes Associated with Arthropods as a Source of New Bioactive Compounds.Current issues in molecular biology · 2024Review
- Renewed interests in the discovery of bioactive actinomycete metabolites driven by emerging technologies.Journal of applied microbiology · 2022Review
- Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents.The Science of the total environment · 2021Review
- Engineering nucleoside antibiotics toward the development of novel antimicrobial agents.The Journal of antibiotics · 2019Review
- Liposidomycin, the first reported nucleoside antibiotic inhibitor of peptidoglycan biosynthesis translocase I: The discovery of liposidomycin and related compounds with a perspective on their application to new antibiotics.The Journal of antibiotics · 2019Review
- Total Synthesis of Mycalisine B.Marine drugs · 2019Article
- Coordinated Biosynthesis of the Purine Nucleoside Antibiotics Aristeromycin and Coformycin in Actinomycetes.Applied and environmental microbiology · 2018Article
- An ATP-Dependent Ligase with Substrate Flexibility Involved in Assembly of the Peptidyl Nucleoside Antibiotic Polyoxin.Applied and environmental microbiology · 2018Article
- Immucillins in Infectious Diseases.ACS infectious diseases · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modified nucleosides produced by Streptomyces and related actinomycetes are widely used in agriculture and medicine as antibacterial, antifungal, anticancer and antiviral agents. These specialized small-molecule metabolites are biosynthesized by complex enzymatic machineries encoded within gene clusters in the genome. The past decade has witnessed a burst of reports defining the key metabolic processes involved in the biosynthesis of several distinct families of nucleoside antibiotics. Furthermore, genome sequencing of various Streptomyces species has dramatically increased over recent years. Potential biosynthetic gene clusters for novel nucleoside antibiotics are now apparent by analysis of these genomes. Here we revisit strategies for production improvement of nucleoside antibiotics that have defined mechanisms of action, and are in clinical or agricultural use. We summarize the progress for genetically manipulating biosynthetic pathways for structural diversification of nucleoside antibiotics. Microorganism-based biosynthetic examples are provided and organized under genetic principles and metabolic engineering guidelines. We show perspectives on the future of combinatorial biosynthesis, and present a working model for discovery of novel nucleoside natural products in Streptomyces.
Indexed as
Identifiers
28260195What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.